click image to enlarge

All products are available for co-development or licensing.

• HER3-targeted Eosomes with doxorubicin payload in preclinical development
• Applications: Triple-negative breast cancer and hard-to-treat HER2⁺ refractory or drug resistant cancers. Both express highly elevated levels of HER3 receptor. Extensive scientific data is available validating the advantages and utility of Eos-001 in cancer cell lines, (breast, ovarian, prostate and glioblastoma) and xenograft mouse models for human cancer
• Observations

• Lower dose of targeted doxorubicin required
• Improved safety profile for targeted doxorubicin (e.g. no damage to heart tissue)
• Eos-001 is highly effective against first-line drug-resistant breast cancer cells and tumors
• Three (3) issued patents and a number of patent applications

Eos-001 Competition: Other Doxorubicin Products
Currently, doxorubicin is marketed either in native form (generic product), as liposomal formulation (branded product), or conjugated to albumin.  In addition, other forms of nanoparticle-based doxorubicin approaches are being investigated. In addition to the unique structural properties of our Eosomes technology, Eos-001 differentiates from other marketed products in very impactful ways:

• Eos-001 is a specifically targeted product that delivers doxorubicin to the interior of the target cell limiting systemic exposure and resulting in higher efficacy at a lower dose and improved safety profile
• Eos-001 is uniquely highly active against HER2⁺ cells and tumors resistant to first-line therapies, and triple-negative breast cancer tumors

• C-Met targeted Eosomes with doxorubicin payload
• Applications: Drug-resistant and metastatic solid tumors that express elevated levels of c-Met
• US and International Patent applications

• C-MET-targeted Eosomes with manganese corrole payload
• Manganese corrole is a porphyrin-like macrocyclic molecule with a manganese ion
• A theranostic product with therapeutic-cancer cell killing, and diagnostic-contrast properties which allows MRI imaging
• Can be applied to a variety of solid tumors, including TNBC and hard-to-treat HER2⁺ drug resistant cancer cells
• Validated in cancer cell lines and xenograft mouse models for human cancer
• Multiple U.S. and International patent applications